The European Medicines Agency's CHMP has recommended approval of Novo Nordisk's Wegovy pill (oral semaglutide) for weight management in the EU. The pill showed a mean weight loss of 16.6% in trials, comparable to the injectable version, and also reduces major cardiovascular risks. It is the first oral GLP-1 treatment endorsed for obesity, with no drug interaction restrictions. Novo Nordisk plans to launch it outside the US in late 2026, aiming to meet rising demand for effective oral obesity treatments.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
